Rockville, MD, Oct. 28, 2024 (GLOBE NEWSWIRE) — The global peripheral stent implant market is set to be valued at US$ 4.11 billion in 2024 and is projected to expand at 6.6% CAGR from 2024 to 2034. Increasing demand for minimally invasive procedures for treating peripheral artery disease is one of the key driving factors driving market progress.

Endovascular inventions such as stent implantation are becoming popular and preferred treatment choices for peripheral artery disease (PAD) over traditional methods of surgical revascularization because they lower the procedural risk associated with endovascular procedures such as accessing the affected artery through a small incision and navigating specialized catheters and guidewires to the site of the blockage.

Endovascular procedures provide patients with less trauma, shorter hospital stays, and quicker recovery periods than open surgery. Studies have demonstrated that endovascular treatments yield long-term results similar to those of surgical revascularization, which lends additional credence to its use. Because of this, medical professionals and institutions are using endovascular procedures such as stent implantation to successfully treat peripheral artery disease while reducing patient morbidity.

For More Insights into the Market, Request a Sample of this Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=10135

Key Takeaways from Market Study 

• The global peripheral stent implant market is analyzed to reach a size of US$ 7.76 billion by the end of 2034.
• The East Asia market is forecasted to expand at a CAGR of 7.9% from 2024 to 2034.
• North America is projected to account for 7% of the global market share in 2024.
• Sales of peripheral stent implants in the United States are forecasted to reach US$ 3.31 billion by the end of 2034.
• Sales of bare metal stents (BMS) are estimated to reach US$ 3.12 billion in 2024.
• By artery type, sales of iliac artery stents are projected to reach US$ 3.68 billion by the end of 2034.
• Based on end user, revenue from hospitals is calculated to reach US$ 4.38 billion by the end of 2034.

“Due to drug-eluting stents’ capacity to lower restenosis rates and enhance long-term patient outcomes, they are now beginning to establish themselves as the preferred product choice in the peripheral stent implant market,” says a Fact.MR analyst

Leading Players Driving Innovation in the Peripheral Stent Implant Market:

Key industry participants like Biotronik SE & Co. KG; W. L. Gore & Associates Inc.; Abbott Laboratories; Cook Medical, Inc.; B. Braun Melsungen AG; Medtronic Plc.; Terumo Medical; Microport Scientific Corporation; Boston Scientific Corporation; Terumo Corporation; iVascular SLU; Cardinal Health, Inc., etc. are driving the peripheral stent implant industry.

Availability of Well-Trained Medical Staff and Access to Sophisticated Technology in Hospitals

Peripheral stent implantation procedures are mostly performed in hospitals, which provide a centralized setting for comprehensive patient care. Hospitals also provide a variety of interventional therapies, such as peripheral stent insertion, since they often have well-trained medical staff and sophisticated technology, such as sophisticated catheterization labs.

Hospitals often have established relationships with medical device manufacturers, which facilitates the acquisition and utilization of peripheral stent implants. Because of reimbursement rules and healthcare financing schemes, hospital-based services often get a significant portion of healthcare spending.

Peripheral Stent Implant Industry News:

• The “AGILITY” investigational device exemption (IDE) trial, which intends to assess the safety and effectiveness of Becton, Dickinson and Company’s vascular-covered stent for the treatment of peripheral artery disease (PAD), enrolled its first patient in March 2024.
• In October 2023, Cordis, a world leader in the development and manufacturing of interventional cardiovascular and endovascular technologies, purchased MedAlliance, a Swiss business that pioneered drug-eluting balloon technology.
• Royal Philips declared in August 2021 that it has signed a deal to purchase Vesper Medical Inc., a US-based provider of minimally invasive peripheral vascular devices.
• The first-in-human (FIH) application of Efemoral Medical’s bioresorbable vascular scaffold system (EVSS) with FlexStep Technology took place in December 2020 as part of the EFEMORAL I FIH clinical research. For a wide range of patients with peripheral arterial disease (PAD), the bioresorbable stent is intended to improve symptoms and avoid reintervention for this traditionally challenging patient population.

Get Customization on this Report for Specific Research Solutions:
https://www.factmr.com/connectus/sample?flag=S&rep_id=10135

 More Valuable Insights on Offer

Fact.MR, in its new offering, presents an unbiased analysis of the peripheral stent implant market, presenting historical demand data (2019 to 2023) and forecast statistics for 2024 to 2034.

The study divulges essential insights into the market based on product (bare metal stents, covered stents, drug-eluting stents), artery (carotid artery stents, fem-pop artery stents, iliac artery stents, infrapop artery stents), and end user (hospitals, ambulatory surgical centers/outpatient), across seven major regions of the world (North America, Western Europe, Eastern Europe, East Asia, Latin America, South Asia & Pacific, and MEA).

Check out More Related Studies Published by Fact.MR Research:

Gastrointestinal stents market is expected to increase at a CAGR of 5.5% from 2022 to 2027 and climb from a market valuation of US$ 516 million in 2022 to US$ 674.3 million by 2027.

Kidney cancer diagnostics market is estimated to be valued at US$ 800 Million in 2022 and increasing at a CAGR of 7% reach US$ 1.4 Billion by 2032.

Anticoagulant reversal drugs market expects to reach US$ 4,601.22 Million by 2033 at a 15.0% CAGR.

Drug discovery technologies market accounts for a revenue of US$ 59 billion in 2022, which is expected to increase to US$ 81.5 billion by the end of 2026.

Antibody drug conjugate contract market demand is anticipated to be valued at US$ 9.2 Billion in 2022, forecast a CAGR of 15.5% to be valued at US$ 38.8 Billion from 2022 to 2032.

About Us:

Fact.MR is a distinguished market research company renowned for its comprehensive market reports and invaluable business insights. As a prominent player in business intelligence, we deliver deep analysis, uncovering market trends, growth paths, and competitive landscapes. Renowned for its commitment to accuracy and reliability, we empower businesses with crucial data and strategic recommendations, facilitating informed decision-making and enhancing market positioning. With its unwavering dedication to providing reliable market intelligence, FACT.MR continues to assist companies in navigating dynamic market challenges with confidence and achieving long-term success. With a global presence and a team of experienced analysts, FACT.MR ensures its clients receive actionable insights to capitalize on emerging opportunities and stay ahead in the competitive landscape.

Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
Sales Team : sales@factmr.com
Follow Us: LinkedIn | Twitter | Blog